(Batifiban) is a new generation of platelet glycoprotein receptor GPIIb/IIIa (also known as: integrin receptor alpha IIb beta 3) antagonist, is currently in clinical phase III trial stage. Clinical dosage form for intravenous administration of intravenous administration.
 

Not only can inhibit integrin receptor alpha IIb beta 3, thereby inhibiting platelet aggregation, and can inhibit the integrin receptor alpha v beta 3, thus inhibiting the growth of vascular smooth muscle, which is also important to prevent the blockage of arterial blood vessel 

One of the indications for the treatment of the patients with the disease , the treatment of the patients with percutaneous coronary intervention (PCI), and the treatment of the disease.